Exenatide vs Semaglutide
Exenatide (GLP-1 receptor agonist) and Semaglutide (GLP-1 receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Page updated 2026-09-20. Latest review of a source entry: 2026-09-20. Editorial method.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Exenatide | Semaglutide |
|---|---|---|
| Compound class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | Not documented | 31 amino acids |
| Molecular weight | Not documented | 4113.6 g/mol |
| Half-life | Not documented | ~7 days |
| Origin | The DURATION-1 trial compared two exenatide formulations over 30 weeks in 295 adults with type 2 diabetes. This entry adds a formulation-focused comparator to the GLP-1 library. | Developed by Novo Nordisk as a long-acting analog of the human incretin hormone GLP-1, building on the earlier once-daily liraglutide. It received first regulatory approvals in 2017 (injectable) and 2019 (oral). |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Exenatide works
Its GLP-1 receptor activity provides the mechanistic context for studies of glucose regulation.
How Semaglutide works
Semaglutide is a structurally modified analog of native glucagon-like peptide-1 (GLP-1) that binds and activates the GLP-1 receptor. Receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on central appetite-regulating pathways to reduce food intake. Its backbone modifications and a C18 fatty-acid (diacid) side chain promote albumin binding and resistance to DPP-4 degradation, giving it a prolonged duration of action.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Exenatide
Semaglutide
What sets each apart
Exenatide
A randomized, open-label non-inferiority study; formulation and trial design matter when interpreting the results. Findings in this population do not establish effects in healthy people.
Semaglutide
Unlike dual or triple agonists, semaglutide is a selective GLP-1 receptor agonist. Its once-weekly dosing and availability in an oral form distinguish it from the older once-daily liraglutide.
Frequently asked questions
What is the evidence context for Exenatide?
A randomized, open-label non-inferiority study; formulation and trial design matter when interpreting the results. Findings in this population do not establish effects in healthy people.
Does this reference establish that a supplier product is equivalent?
No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.
What is semaglutide and what receptor does it target?
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist derived from the native GLP-1 peptide with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin to extend its half-life. In research it is studied as a reference GLP-1 agonist in models of glucose regulation, appetite/food intake, and body-weight change. It is the mono-agonist against which many newer multi-receptor compounds are benchmarked.
What does semaglutide's long half-life mean for research design?
Semaglutide has a reported plasma half-life of roughly 7 days (about 155-184 hours), which is why once-weekly administration is used in the published literature. Steady-state concentrations are typically reached after about 4-5 weeks at a given dose level, so study designs generally include a multi-week dose-escalation before any maintenance-phase readout. This slow kinetics also means washout after discontinuation spans several weeks.
How is semaglutide dose-escalated in the research literature?
Published protocols use a stepwise weekly escalation, commonly 0.25 mg, then 0.5, 1.0, 1.7, and up to 2.4 mg once weekly, with each step typically held about 4 weeks. Escalation is used in the literature to reduce gastrointestinal tolerability issues rather than starting at the top dose. These are reference figures for research context only, not dosing guidance for humans.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.
Linked publications
Publications recorded on each compound's profile, including original studies and reviews. These are background sources for the separate compounds; listing them together does not establish a direct comparison, a combination study, or equivalent evidence. Read the study design and limitations before interpreting a finding.